Protalix BioTherapeutics (PLX) Net Income Growth (1y) (2011 - 2026)
Protalix BioTherapeutics (PLX) Net Income Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -0.46% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | 63.48% |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 1,228.66% |
| 10 | Protalix BioTherapeutics | 192.84 Mn | 182.04 Mn | 29.62 Mn | 608.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 608.10% |
| Dec 31, 2025 | -133.17% |
| Sep 30, 2025 | -30.47% |
| Jun 30, 2025 | 117.93% |
| Mar 31, 2025 | 21.24% |
| Dec 31, 2024 | 153.70% |
| Sep 30, 2024 | 287.47% |
| Jun 30, 2024 | -113.59% |
| Mar 31, 2024 | -46.76% |
| Dec 31, 2023 | -526.92% |
| Sep 30, 2023 | 48.08% |
| Jun 30, 2023 | 403.88% |
| Mar 31, 2023 | -36.96% |
| Dec 31, 2022 | 44.92% |
| Sep 30, 2022 | 16.95% |
| Jun 30, 2022 | 53.08% |
| Mar 31, 2022 | 61.00% |
| Dec 31, 2021 | -203.24% |
| Sep 30, 2021 | 5.71% |
| Jun 30, 2021 | -171.47% |